TMCnet News
Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in BostonMartinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 4th TCR-based Therapies for Solid Tumors Summit in Boston from April 3 to 5, 2023. On April 4, 2023, Prof. Schendel will first join the Industry Leaders’ Fireside Chat ”What’s Next for T-Cell Receptor Therapies?”, followed by her presentation (see details below). TCR-based Therapies for Solid Tumors Summit --- end of press release --- About Medigene This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only. Medigene Pamela Keck LifeSci Advisors Sandya von der Weid In case you no longer wish to receive any information about Medigene, please inform us by e-mail ([email protected]). We will then delete your address from our distribution list. ![]() |